COVID-19 Archives - Page 3 of 18

Markets

BTIG cuts Talis Biomedical to sell; PT $1

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “sell” from “neutral” with a price target of $1, citing a delay in the beta-phase rollout of the Talis One COVID-19 diagnostic, which was planned for the first quarter...

March 18, 2022

Developments

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Closely-held Cytovale announced that a new study of its investigational IntelliSep test has been published in the peer-reviewed journal, PLOS ONE. The study demonstrated that the IntelliSep test has the potential to...

March 17, 2022

Markets

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

Raymond James downgraded Cardiol Therapeutics (TSX:CRDL) to “market perform” from “outperform” and trimmed its price target to $4 (Canadian) from $5, citing a slower than expected enrollment in Cardiol’s LANCER clinical...

March 16, 2022

Markets

SVB Leerink starts Pardes Biosciences at OP; PT $18

SVB Leerink launched coverage of Pardes Biosciences (NASDAQ:PRDS) with an “outperform” rating and $18 price target. The stock closed at $5.54 on March 14. Pardes is a clinical-stage biopharmaceutical company created to...

March 15, 2022

Developments

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Omicron variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection...

March 11, 2022

Developments

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Altamira Therapeutics’ (NASDAQ:CYTO) affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of its Bentrio nasal spray in COVID-19 patients. The COVAMID study is a...

March 9, 2022

Feature

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Ampio Pharmaceuticals (NYSE American:AMPE), citing a significant impact from COVID-19 on its second confirmatory Phase 3 trial of Ampion for the treatment of severe osteoarthritis of the knee (OAK), hopes to meet with...

March 8, 2022

Markets

AGP ups T2 BioSystems to buy; Canaccord cuts PT to $1.50 from $3

Following the fourth quarter report for T2 BioSystems (NASDAQ:TTOO), Alliance Global Partners upgraded T2 to “buy” from “neutral” and raised its price target to 70 cents from 55 cents, while Canaccord Genuity reduced...

February 18, 2022

Feature

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Sigyn Therapeutics (OTC:SIGY) hopes to file in the second quarter this year an investigational device exemption (IDE) with the FDA to initiate human clinical studies of its Sigyn Therapy, a dual-function blood...

February 15, 2022

Markets

Maxim recalibrates biotech; lowering PTs as industry multiples contract

In an industry wide series of research reports, Maxim Group analyst Jason McCarthy, Ph.D., lowered price targets on stocks in his coverage universe, saying industry multiples have contracted but company outlooks remain...

February 2, 2022

Tag - COVID-19

BTIG cuts Talis Biomedical to sell; PT $1

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

SVB Leerink starts Pardes Biosciences at OP; PT $18

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

AGP ups T2 BioSystems to buy; Canaccord cuts PT to $1.50 from $3

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Maxim recalibrates biotech; lowering PTs as industry multiples contract

General

More